… This case series aims to describe micro-dosing to initiate buprenorphine/naloxone in a
fentanyl exposed population in an outpatient setting. We describe both patients on OAT, either …

… and fentanyl exposure were correlated with lifetime use of diverted buprenorphine/naloxone,
but none correlated with use of diverted buprenorphine/naloxone in the past 2 months. …

… formulations indicated for OUD treatment (ie, sublingual buprenorphine/naloxone film or
tablets and buprenorphine monoproducts). Products specifically FDA-approved for pain …

… a relapse to heroin use and was later stabilised on buprenorphine/naloxone at a daily … to
fentanyl use over the last 2 years. At admission, her urine was positive for cocaine and fentanyl, …

… to fentanyl’s lipophilicity, which leads to protracted and highly variable renal clearance among
individuals with fentanyl use … who use illicit fentanyl onto buprenorphine/naloxone. Am J …

… To examine whether fentanyl use is associated with buprenorphine treatment outcomes, we
… opioid use among patients initiating treatment with buprenorphine who had either fentanyl …

… of buprenorphine-precipitated withdrawal after fentanyl use despite extended (24–48hours)
periods of fentanyl … for fentanyl-related precipitated withdrawal, and to compare conventional …

… These include a transdermal fentanyl bridge, a micro-induction technique, and a … use
of a transdermal fentanyl patch to transition patients from methadone to buprenorphine/naloxone. …

… showed buprenorphine displacement of fentanyl binding was … tered in clinical use, but
buprenorphine binding was displaced … of naloxone to reverse established buprenorphine effects. …

… buprenorphinenaloxone and the date of service (refill date) for the succeeding pharmacy
claim for buprenorphine-naloxone. … use occurred with the fentanyl patch and oral transmucosal …